Online inquiry

IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11930MR)

This product GTTS-WQ11930MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets GUCY2C gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_004963.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2984
UniProt ID P25092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ11930MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14378MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ4473MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ13415MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ8245MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HLX10
GTTS-WQ6134MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CP-675
GTTS-WQ5575MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP-771
GTTS-WQ8648MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ10541MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-3015014
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW